Dominique De Wit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dominique De Wit has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Amandine Legat
Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium
1 shared publicationMarcelle Van Mechelen
GlaxoSmithKline Biologicals, Rixensart, Belgium
1 shared publicationMichel Goldman
Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium
1 shared publication- Michel Goldman
Institute for Interdisciplinary Innovation in Healthcare, Université Libre de Bruxelles, Brussels, Belgium
1 shared publication Philippe Hermand
GlaxoSmithKline Biologicals, Rixensart, Belgium
1 shared publicationSéverine Thomas
Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium
1 shared publication
Latest Publications
- Open Access
- 3 March 2010
- Published by Wiley in European Journal of Immunology
- Vol. 40 (3) , 797-802
CD14‐independent responses induced by a synthetic lipid A mimetic
CRX‐527 belongs to a new family of synthetic lipid A mimetics, the aminoalkyl glucosaminide 4‐phosphates, which are considered as potential vaccine adjuvants or stand‐alone immunotherapeutics to harness innate immune defenses. Since natural lipid A from bacterial LPS depends on membrane‐bound (mCD14) or soluble CD14 for its TLR4 ligand activity, we investigated the involvement of both forms of CD14 in the responses elicited by CRX‐527. First, we found that CRX‐527 induces NF‐κB and interferon regulatory factor‐3 (IRF‐3) activation in human embryonic kidney cells transfected with TLR4 and MD‐2 genes alone, whereas the responses to LPS require either co‐transfection of the gene encoding mCD14 or addition of soluble CD14. We then observed that monocyte‐derived DC, which are devoid of mCD14 respond to CRX‐527 but not to LPS in serum‐free medium. Furthermore, we found that, in contrast to LPS, CRX‐527 induces the production of cytokines in whole blood of a patient with paroxysmal nocturnal hemoglobinuria, a disease in which mCD14‐dependent responses are defective. Finally, we demonstrated that splenocytes from CD14‐deficient mice produce cytokines in response to CRX‐527 but not to LPS. We conclude that the lipid A mimetic CRX‐527 does not require the CD14 co‐receptor to elicit TLR4‐mediated responses.
- 3 March 2010
- Published by Wiley in European Journal of Immunology
- Vol. 40 (3) , 797-802
Open AccessCD14‐independent responses induced by a synthetic lipid A mimetic
CRX‐527 belongs to a new family of synthetic lipid A mimetics, the aminoalkyl glucosaminide 4‐phosphates, which are considered as potential vaccine adjuvants or stand‐alone immunotherapeutics to harness innate immune defenses. Since natural lipid A from bacterial LPS depends on membrane‐bound (mCD14) or soluble CD14 for its TLR4 ligand activity, we investigated the involvement of both forms of CD14 in the responses elicited by CRX‐527. First, we found that CRX‐527 induces NF‐κB and interferon regulatory factor‐3 (IRF‐3) activation in human embryonic kidney cells transfected with TLR4 and MD‐2 genes alone, whereas the responses to LPS require either co‐transfection of the gene encoding mCD14 or addition of soluble CD14. We then observed that monocyte‐derived DC, which are devoid of mCD14 respond to CRX‐527 but not to LPS in serum‐free medium. Furthermore, we found that, in contrast to LPS, CRX‐527 induces the production of cytokines in whole blood of a patient with paroxysmal nocturnal hemoglobinuria, a disease in which mCD14‐dependent responses are defective. Finally, we demonstrated that splenocytes from CD14‐deficient mice produce cytokines in response to CRX‐527 but not to LPS. We conclude that the lipid A mimetic CRX‐527 does not require the CD14 co‐receptor to elicit TLR4‐mediated responses.
- 28 December 2009
- Published by Springer Nature
- Vol. 626, 103-116
Adjuvant Activity on Human Cells In Vitro
Efficient vaccines against intracellular microbes or tumors will be based on innovative adjuvants able to induce efficient activation of dendritic cells. Indeed, natural or synthetic products activating Toll-like receptors (TLR) on dendritic cells (DCs) are currently in development for this purpose. Herein, we describe in vitro assays on human cells which might be useful for the preclinical screening and assessment of potential DC activators.
- 28 December 2009
- Published by Springer Nature
- Vol. 626, 103-116
Adjuvant Activity on Human Cells In Vitro
Efficient vaccines against intracellular microbes or tumors will be based on innovative adjuvants able to induce efficient activation of dendritic cells. Indeed, natural or synthetic products activating Toll-like receptors (TLR) on dendritic cells (DCs) are currently in development for this purpose. Herein, we describe in vitro assays on human cells which might be useful for the preclinical screening and assessment of potential DC activators.